Non-squamous Non-small-cell Lung Cancer Clinical Trial
Official title:
Open-label, Phase 2 Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)
Primary objective： ·To assess the antitumor activity of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC population. Secondary objectives： To assess the safety and tolerability of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC population. To assess the pharmacokinetic (PK) characteristic of tusamitamab ravtansine in combination with sintilimab and tusamitamab ravtansine in combination with sintilimab, platinum-based chemotherapy and pemetrexed in the NSQ NSCLC population.
The expected duration of the study intervention for participants may vary based on progression date; median expected duration of study per participant is estimated 10 months (up to 1 month for screening, a median of 6 months for treatment, and a median of 3 months for end-of-treatment assessments and safety follow-up visit). ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04504916 -
A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)
|
Phase 2 | |
| Active, not recruiting |
NCT04396457 -
Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901
|
Phase 2 | |
| Recruiting |
NCT05338619 -
A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy
|
Phase 2 | |
| Terminated |
NCT04265534 -
KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC
|
Phase 2 | |
| Active, not recruiting |
NCT05258279 -
Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations
|
Phase 2 | |
| Not yet recruiting |
NCT04453423 -
Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.
|
Phase 2 | |
| Terminated |
NCT04173338 -
Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma
|
Phase 1 | |
| Terminated |
NCT04698681 -
NGS Screening Protocol to Detect Mutation of KEAP1 or NRF2/NFE2L2 Genes for the KEAPSAKE (CX-839-014) Trial
|
||
| Active, not recruiting |
NCT04211090 -
Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC
|
Phase 2 | |
| Recruiting |
NCT04619433 -
A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
|
Phase 3 | |
| Recruiting |
NCT04084717 -
Study of Crizotinib for ROS1 and MET Activated Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT04958811 -
Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC
|
Phase 2 | |
| Completed |
NCT00152477 -
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
|
Phase 2 | |
| Completed |
NCT04012619 -
Anlotinib Hydrochloride Combined With AP in Stage IIIB/IIIC/IV Non-squamous Non-small-cell Lung Cancer
|
Phase 1 | |
| Recruiting |
NCT05403554 -
A Study of NI-1801 in Patients With Mesothelin Expressing Solid Cancers
|
Phase 1 | |
| Completed |
NCT05318443 -
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
|
Phase 3 |